Taking a “Development by Design” Approach to Cell Therapies

Taking a “Development by Design” Approach to Cell Therapies

February 1, 2015

NeoStem is following two paths, pursuing its own cell therapy pipeline and exploring contract services through its contract development and manufacturing organization (CDMO) subsidiary, Progenitor Cell Therapy (PCT).

Click here to read the full article.